Why Policybazaar Share Price Fell 30%: IRDAI Rules Explained

PB Fintech shares (Policybazaar) crashed 30% today, after insurance regulator IRDAI proposed a major overhaul of how insurance distributors are paid. The Policybazaar parent's stock had closed at ₹1,886.30 in the previous session before falling sharply as investors assessed the potential impact on its commission income.

The concern is fairly simple. Policybazaar earns money when customers buy or renew insurance policies through its platform. IRDAI now wants to put stricter limits on how much insurers can pay distributors such as Policybazaar for selling those policies.

The proposed rules are not final yet. They are part of IRDAI's consultation paper titled "Recalibrating Economics of Insurance Distribution", released on September 23. But if implemented in their current form, they could change the economics of some of Policybazaar's most important businesses.

How Does Policybazaar Make Money From Insurance?

Policybazaar does not manufacture most of the insurance policies shown on its platform.

Instead, insurers such as HDFC Life, ICICI Lombard, Niva Bupa and others provide the policies. Policybazaar helps customers compare, buy and renew them.

In return, the insurer pays Policybazaar a commission or distribution fee. Suppose you buy a health insurance policy with an annual premium of ₹10,000 through Policybazaar. You still pay ₹10,000 to the insurance company. The insurer then pays Policybazaar separately for bringing and servicing that customer.

This commission income is an important part of PB Fintech's insurance business. That is why today's regulatory proposal matters.

What Is IRDAI Actually Changing?

The easiest way to understand the change is to compare the existing system with what IRDAI is proposing.

Under the current framework, insurers have considerable flexibility to decide commission structures through a board-approved policy. Commissions form part of the insurer's overall Expenses of Management, or EoM, limit, but there is no equivalent set of hard product-by-product commission ceilings like those now being proposed.

IRDAI now wants to bring back much tighter product and distribution-channel specific limits.

So the fundamental change is this: Today, an insurer largely decides how much it wants to pay Policybazaar while staying within the broader regulatory expense framework.

Under the proposal, even if the insurer wants to pay more, it may not be allowed to cross IRDAI's product-specific ceiling.

How Could This Change What Policybazaar Earns?

Take a simple example. Assume a customer buys a health insurance policy with an annual premium of ₹10,000.

If an insurer currently pays a distributor 25% on that particular policy, the distributor earns: ₹10,000 × 25% = ₹2,500

Under IRDAI's proposed 15% ceiling: ₹10,000 × 15% = ₹1,500

The customer still pays ₹10,000. The insurance coverage does not automatically change. What changes is the amount the insurer can pay the distributor.

In this example, Policybazaar-type distribution revenue would fall from ₹2,500 to ₹1,500 on the same premium.

This is only an illustration. PB Fintech does not publicly disclose one uniform commission percentage across every insurer and health insurance product, so the exact company-wide revenue impact cannot be calculated simply by applying 15%. But it explains what the market is worried about.

Why Health Insurance Is Particularly Important for PB Fintech

The timing of the proposed rules matters because health and protection insurance have been among PB Fintech's strongest-growing businesses.

In Q1 FY27, PB Fintech's total insurance premium grew 41% year-on-year to ₹8,372 crore.

More importantly, new protection premium, which includes health and term insurance, grew 53%. Within this, new health insurance premium increased 59% year-on-year. PB Fintech's core insurance revenue grew 46%.

That means the regulatory pressure is arriving precisely where PB Fintech has been seeing some of its strongest growth.

If health premium keeps growing rapidly but the commission earned on every ₹100 of premium falls, PB Fintech could potentially process significantly more business without revenue growing at the same pace. That is a very different growth equation.

The Bigger Risk Could Be Health Renewals

New policy commissions are only one part of the story. The proposed 5% ceiling on health renewals could be equally important for PB Fintech because renewal revenue has increasingly become an important contributor to its long-term profitability.

PB Fintech's core renewal and trail revenue on a rolling 12-month basis reached ₹1,003 crore in Q1 FY27, up from ₹725 crore a year earlier. Within insurance, the company said renewal revenue growth was 55% year-on-year and described renewals as a key driver of long-term profit growth.

Why are renewals valuable?

Selling a new policy can require advertising, lead generation, sales staff, customer support and other acquisition costs.

When the same customer renews the policy next year, Policybazaar already has the relationship. It does not necessarily need to spend the same amount to acquire that customer again.

That can make renewal income particularly valuable from a profitability perspective.

IRDAI is proposing to cap the commission paid to distribution entities on individual health renewals at 5% of premium.

Importantly, PB Fintech's ₹1,003 crore renewal and trail revenue includes more than just individual health renewals. So it would be incorrect to apply the 5% cap directly to that entire number.

But the direction of the risk is clear. If commissions on a profitable renewal stream decline, the impact could extend beyond revenue and into margins.

Term and Motor Insurance Face Pressure Too

Health is not the only area affected. For multi-year individual pure-term insurance, IRDAI proposes a maximum first-year commission of 25% for distribution entities, followed by a 7.5% renewal commission. Agents would be permitted somewhat higher limits.

Motor insurance could see an even more visible change.

For third-party insurance on new vehicles, the proposed commission for distribution entities is zero. For new-vehicle own-damage, personal accident and legal liability cover, the proposed ceiling is 5%.

Policybazaar can still sell these policies. The issue is that the amount it can earn from distributing them could become smaller.

Why Can Lower Commissions Hurt Profit More Than Revenue?

This is the most important point behind the sharp PB Fintech share price reaction. Suppose Policybazaar currently earns ₹20 from a policy and spends ₹15 acquiring, selling and servicing that business.

Its contribution is ₹5. Now imagine regulation reduces its revenue to ₹17, but many of its employee, technology, servicing and marketing costs remain.

Its contribution falls from ₹5 to ₹2.

Revenue fell only 15%, but the contribution fell 60%. That is why investors are not looking only at the reduction in commissions. They are looking at the possible effect on operating leverage and future profitability.

Jefferies estimates that a 10% reduction in new-business commission rates could result in roughly a 10% to 12% earnings impact for PB Fintech and Turtlemint. This is a brokerage estimate rather than guidance from PB Fintech, but it demonstrates why relatively small changes in commission rates can matter materially for distributors.

Why Is IRDAI Cutting Insurance Commissions?

From IRDAI's perspective, the objective is not to specifically target Policybazaar.

The regulator is trying to reduce insurance distribution costs, discourage mis-selling and ensure that commissions better reflect the amount of work required to sell and service different insurance products.

One statistic explains some of the regulator's concern.

Between FY23 and FY25, motor insurance premium reportedly increased around 34%, while commissions paid to distributors increased around 259%. IRDAI cited the sharp divergence while making the case for reforming distribution economics.

IRDAI had moved towards a more flexible commission regime in 2023. The latest proposal effectively moves the industry back towards tighter product and channel-specific commission ceilings.

What Should PB Fintech Investors Track Now?

• Final IRDAI rules: These are proposals, not final regulations. The eventual commission ceilings and implementation timeline can still change.
• Health commission impact: Health is one of Policybazaar's fastest-growing categories, making this one of the most important areas to monitor.
• Renewal economics: PB Fintech has identified renewals as a major long-term profit driver. Any meaningful reduction in renewal take rates could change that profitability equation.
• Product mix: The impact will depend heavily on how much premium PB Fintech generates from health, term, motor, savings and other insurance categories.
• Management commentary: Investors will need PB Fintech to quantify how the proposed limits compare with its existing commission rates. Until that disclosure arrives, precise earnings estimates will involve assumptions.

Author's Take

The  30% fall in PB Fintech shares looks extreme if the IRDAI consultation paper is viewed merely as another insurance regulation.

It looks more understandable when viewed through Policybazaar's business model.

The company has built a large distribution platform where rising insurance volumes, strong health growth and increasingly valuable renewal revenues have been supporting the path towards higher profits. The proposed rules potentially reduce how much Policybazaar can earn from each unit of premium across several important categories.

But there is also an important distinction investors should not miss.

IRDAI has released a consultation paper, not final regulations, and PB Fintech has not yet disclosed the exact financial impact of these proposed caps. It would therefore be premature to assume that every reduction in headline commission limits will translate directly into an equivalent fall in company revenue.

The real question is no longer simply whether Policybazaar can keep selling more insurance.

It is whether it can continue growing premiums at strong rates while earning less on each policy and still protecting margins.

That is the number investors need to watch as the regulatory proposal moves towards its final form.